Page last updated: 2024-08-23

paclitaxel and Left Ventricular Dysfunction

paclitaxel has been researched along with Left Ventricular Dysfunction in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.57)18.2507
2000's18 (64.29)29.6817
2010's9 (32.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dang, CT; Eaton, A; Hudis, CA; Liu, JE; Oeffinger, KC; Singh, JC; Steingart, RM; Wang, R; Yu, AF1
Atkins, JN; Biggs, DD; Brufsky, AM; Cecchini, RS; Fehrenbacher, L; Flynn, PJ; Ganz, PA; Geyer, CE; Gross, HM; Jeong, JH; Mamounas, EP; Polikoff, J; Rastogi, P; Romond, EH; Seay, TE; Swain, SM; Wade, JL; Wahl, TA; Wolmark, N; Zapas, JL1
Braunstein, LZ; Cahlon, O; Dang, CT; Eaton, A; Ho, AY; Lee Chuy, K; Liu, JE; Mara, E; Oeffinger, KC; Steingart, RM; Thor, ME; Yu, AF1
Baliulis, G; Corbett, S; Curzen, N; Kaarne, M; Olsen, S; Rawlins, J; Roubelakis, A1
Albain, K; Burstein, HJ; Carey, LA; Dang, C; Ellis, M; Groarke, J; Guo, H; Hudis, C; Krop, I; Marcom, K; Miller, K; Moslehi, J; Moy, B; Najita, J; Rugo, H; Shapira, I; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, D1
Chamorey, E; Ferrero, JM; Milano, G1
Beer, LA; Domchek, S; Kossenkov, AV; Ky, B; Liu, Q; Luning Prak, E; Speicher, DW1
Gokoz-Dogu, G; Saricopur, A; Senol, H; Yaylali, YT; Yurtdas, M1
Abbate, A; Appleton, DL; Cowley, MJ; Di Sciascio, G; Goudreau, E; Lipinski, MJ; Nusca, A; Varma, A; Vetrovec, GW; Wittkamp, MJ1
Chen, YH; Li, J; Liang, D; Liu, Y; Peng, L; Xiao, J; Zhang, H; Zhao, H; Zhou, Z1
Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J1
Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M1
Dakhil, SR; Davidson, NE; Gersh, BJ; Ingle, JN; Jaffe, AS; Kaufman, PA; Martino, S; Perez, EA; Rodeheffer, RJ; Suman, VJ1
Hudis, C; Keefe, D; Lieberman, G; Paton, V; Seidman, A; Tripathy, D1
Albertal, M; Balino, PP; Belardi, JA; Berrocal, D; Cura, F; Fava, C; Grinfeld, L; Mendiz, O; Padilla, L; Pascua, JA; Solioz, G1
Jang, Y; Jeon, DW; Kim, BO; Ko, YG; Kwon, HM; Lee, SH; Park, SH; Ryu, SK; Yang, JY; Yoon, JH1
Brown, A; Bryant, J; Ewer, M; Fehrenbacher, L; Geyer, CE; Keefe, D; Mamounas, EP; Rastogi, P; Romond, E; Seay, TE; Shannon, RP; Swain, SM; Tan-Chiu, E; Vogel, VG; Wolmark, N; Yothers, G1
Benassi, A; Ewing, LG; Gioia, G; Levite, HA; Matthai, W; Rana, H1
Carey, LA; Collichio, F; Dees, EC; Dressler, L; Gatti, L; Graham, ML; Ivanova, A; Kelly, H; Kimmick, G; Sawyer, L1
Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Park, KH; Park, SJ; Park, SW1
Thomas, M1
Benassi, A; Dralle, J; Gillin, K; Gioia, G; Gioia, MF; Matthai, W; White, J1
Currie, V; D'Andrea, G; Dang, C; Dickler, M; Drullinsky, P; Fornier, M; Gilewski, T; Hudis, C; Lake, D; Mills, N; Moynahan, ME; Norton, L; Panageas, K; Robson, M; Seidman, A; Sklarin, N; Steingart, R; Sugarman, S; Troso-Sandoval, T; Wasserheit-Leiblich, C1
Hoefnagel, CA; ten Bokkel Huinink, WW; Valdés Olmos, RA1
Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM1
Bdolah-Abram, T; Burtness, BA; D'Andrea, E; Gollerkeri, A; Lee, FA; Psyrri, A; Rose, M1
Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G1
Hamazoe, R; Komuro, I; Murata, Y; Shimoyama, M; Sumi, KI1

Trials

10 trial(s) available for paclitaxel and Left Ventricular Dysfunction

ArticleYear
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitax
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Dec-10, Volume: 35, Issue:35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Survivors; Cardiovascular System; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left

2017
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left

2003
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
    British journal of cancer, 2004, Jul-05, Volume: 91, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Risk Factors; Ventricular Dysfunction, Left

2004
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left

2004
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
    Clinical breast cancer, 2004, Volume: 5, Issue:4

    Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Heart; Heart Diseases; Heart Failure; Humans; Immunohistochemistry; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left

2004
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-01, Volume: 23, Issue:31

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Heart; Heart Failure; Humans; Incidence; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left

2005
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Clinical breast cancer, 2006, Volume: 7, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; North Carolina; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left

2006
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-10, Volume: 26, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Gene Amplification; Heart; Heart Failure; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left

2008
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Bone marrow transplantation, 2000, Volume: 25, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Synergism; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiotherapy; Risk; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left

2000
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
    British journal of cancer, 2000, Volume: 83, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left

2000

Other Studies

18 other study(ies) available for paclitaxel and Left Ventricular Dysfunction

ArticleYear
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    The oncologist, 2017, Volume: 22, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Female; Heart; Heart Failure; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left

2017
Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2019, Volume: 32, Issue:4

    Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Echocardiography, Doppler; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Trastuzumab; Ventricular Dysfunction, Left

2019
Coronary artery rupture caused by stent infection: a rare complication.
    Circulation, 2015, Apr-07, Volume: 131, Issue:14

    Topics: Angina, Unstable; Anti-Bacterial Agents; Chest Pain; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Drug-Eluting Stents; Emergencies; Floxacillin; Fusidic Acid; Humans; Internal Mammary-Coronary Artery Anastomosis; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis-Related Infections; Rupture, Spontaneous; Staphylococcal Infections; Ultrasonography; Ventricular Dysfunction, Left

2015
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    JAMA oncology, 2016, Volume: 2, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Trastuzumab; Treatment Outcome; United States; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult

2016
Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
    JAMA oncology, 2016, Volume: 2, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left; Ventricular Function, Left

2016
Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
    Circulation research, 2016, Oct-28, Volume: 119, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cardiomyopathies; Case-Control Studies; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Heart Failure; Humans; Immunoglobulin E; Immunoglobulin G; Middle Aged; Paclitaxel; Proteomics; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left; Young Adult

2016
Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines.
    Arquivos brasileiros de cardiologia, 2016, Volume: 107, Issue:5

    Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Breast Neoplasms; Case-Control Studies; Cyclophosphamide; Diastole; Doxorubicin; Echocardiography; Female; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Systole; Ventricular Dysfunction, Left; Ventricular Function, Left

2016
Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention.
    The American journal of cardiology, 2008, Sep-15, Volume: 102, Issue:6

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Diabetes Mellitus; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Paclitaxel; Retrospective Studies; Sirolimus; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left

2008
Taxol, a microtubule stabilizer, improves cardiac contractile function during ischemia in vitro.
    Pharmacology, 2010, Volume: 85, Issue:5

    Topics: Animals; Calcium Signaling; Cells, Cultured; Electron Transport Chain Complex Proteins; Heart Failure; Heart Ventricles; Homeostasis; In Vitro Techniques; Male; Microtubules; Mitochondria, Heart; Myocardial Contraction; Myocardial Ischemia; Myocytes, Cardiac; Paclitaxel; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Time Factors; Tubulin Modulators; Ventricular Dysfunction, Left

2010
Use of drug-eluting stents for the treatment of in-stent restenosis in routine clinical practice.
    Coronary artery disease, 2005, Volume: 16, Issue:5

    Topics: Aged; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Practice Patterns, Physicians'; Retrospective Studies; Sirolimus; Stents; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left

2005
Sirolimus- versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis.
    Cardiology, 2005, Volume: 104, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Sirolimus; Stents; Treatment Outcome; Ventricular Dysfunction, Left

2005
Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2006, Volume: 68, Issue:3

    Topics: Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Cardiomyopathies; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Female; Follow-Up Studies; Heart Failure; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Paclitaxel; Prosthesis Design; Research Design; Severity of Illness Index; Sirolimus; Stents; Stroke Volume; Survival Rate; Treatment Outcome; United States; Ventricular Dysfunction, Left

2006
Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions.
    The American journal of cardiology, 2006, Oct-01, Volume: 98, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Korea; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Revascularization; Outcome Assessment, Health Care; Paclitaxel; Prospective Studies; Prosthesis Design; Sirolimus; Stents; Ventricular Dysfunction, Left

2006
Revascularization for ischemic LV dysfunction: stents or surgery?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jul-01, Volume: 70, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Cardiomyopathies; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Bypass; Humans; Myocardial Ischemia; Paclitaxel; Patient Selection; Prosthesis Design; Radiography; Severity of Illness Index; Sirolimus; Stents; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left

2007
Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jul-01, Volume: 70, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiomyopathies; Cardiovascular Agents; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Paclitaxel; Prosthesis Design; Research Design; Retrospective Studies; Severity of Illness Index; Sirolimus; Stents; Time Factors; Treatment Outcome; United States; Ventricular Dysfunction, Left

2007
Cardiac dysfunction in cancer patients receiving paclitaxel.
    European journal of nuclear medicine, 1998, Volume: 25, Issue:4

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Female; Heart Failure; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stroke Volume; Ventricular Dysfunction, Left

1998
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function.
    Bone marrow transplantation, 2000, Volume: 26, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Rate; Ventricular Dysfunction, Left

2000
Docetaxel induced cardiotoxicity.
    Heart (British Cardiac Society), 2001, Volume: 86, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Ventricular Dysfunction, Left

2001